CRISPR Therapeutics (CRSP)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Gene Editingsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-15. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 12/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 19.45% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Where Will CRISPR Therapeutics Stock Be in 2030?
- Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.
- CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
- Is CRISPR Therapeutics (CRSP) Undervalued As CASGEVY Hopes Face Market Doubts?
- CRISPR Therapeutics (CRSP) Stock Looks Rich On Upcoming CTX310 Trial Data
- Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer
- CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
- Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Advancements in CRISPR-based in vivo gene therapy for hemophilia. — Front Genome Ed 2026 PMID 42787633
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for CRISPR Therapeutics.
Full CRSP Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.